Evidence map›Paper›PMID 35236094›Full record

ArticleCirculation2022

Heteroplasmy of Wild-Type Mitochondrial DNA Variants in Mice Causes Metabolic Heart Disease With Pulmonary Hypertension and Frailty.

Ana Victoria Lechuga-Vieco, Ana Latorre-Pellicer, Enrique Calvo, Carlos Torroja, Juan Pellico, Rebeca Acín-Pérez, María Luisa García-Gil, Arnoldo Santos, Navratan Bagwan, Elena Bonzon-Kulichenko and 8 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Roles of Mitochondrial DNA Damage in Kidney Diseases: A New Biomarker.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Ana Victoria Lechuga-ViecoCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).ORCID 0000-0001-5546-9752
Ana Latorre-PellicerUnit of Clinical Genetics and Functional Genomics, Department of Pharmacology-Physiology, School of Medicine, University of Zaragoza, IIS-Aragon, Zaragoza, Spain (A.L.-P.).ORCID 0000-0002-4703-6620
Enrique CalvoCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).
Carlos TorrojaCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).ORCID 0000-0001-8914-3400
Juan PellicoCiber de Enfermedades Respiratorias (CIBERES), Madrid, Spain (A.V.L.-V., J.P., A.S., J.R.-C.).ORCID 0000-0003-2787-8641
Rebeca Acín-PérezCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).ORCID 0000-0001-9553-8337
María Luisa García-GilCentro Nacional de Microscopia Electrónica (ICTS-CNME), Universidad Complutense de Madrid, Spain (M.L.G.-G.).
Arnoldo SantosCiber de Enfermedades Respiratorias (CIBERES), Madrid, Spain (A.V.L.-V., J.P., A.S., J.R.-C.).
Navratan BagwanCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).
Elena Bonzon-KulichenkoCiber de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (E.B.-K., J.V.).ORCID 0000-0003-0852-7520
Ricardo MagniCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).
Marina BenitoCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).ORCID 0000-0002-0661-755X
Raquel Justo-MéndezCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).ORCID 0000-0002-7648-3550
Anna Katharina SimonThe Kennedy Institute of Rheumatology, NDORMS, University of Oxford, UK (A.V.L.-V., A.K.S.).
Fátima Sánchez-CaboCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.V.L.-V., R.M., M.B., R.J.-M., J.R.-C.).
Jesús VázquezCiber de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (E.B.-K., J.V.).ORCID 0000-0003-1461-5092
Jesús Ruíz-CabelloCiber de Enfermedades Respiratorias (CIBERES), Madrid, Spain (A.V.L.-V., J.P., A.S., J.R.-C.).ORCID 0000-0001-8681-5056
José Antonio EnríquezCiber de Fragilidad y Envejecimiento Saludable (CIBERFES) Madrid, Spain (J.A.E.).ORCID 0000-0002-3671-2961
Instituto de Salud Carlos III · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable · ESIkerbasque · ESKing's College London · GBTécnicas y Servicios de Ingeniería (Spain) · ESUniversidad Complutense de Madrid · ESUniversidad de Zaragoza · ESUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn most eukaryotic cells, the mitochondrial DNA (mtDNA) is transmitted uniparentally and present in multiple copies derived from the clonal expansion of maternally inherited mtDNA. All copies are therefore near-identical, or homoplasmic. The presence of >1 mtDNA variant in the same cytoplasm can arise naturally or result from new medical technologies aimed at preventing mitochondrial genetic diseases and improving fertility. The latter is called divergent nonpathologic mtDNA heteroplasmy (DNPH). We hypothesized that DNPH is maladaptive and usually prevented by the cell.

methodsWe engineered and characterized DNPH mice throughout their lifespan using transcriptomic, metabolomic, biochemical, physiologic, and phenotyping techniques. We focused on in vivo imaging techniques for noninvasive assessment of cardiac and pulmonary energy metabolism.

resultsWe show that DNPH impairs mitochondrial function, with profound consequences in critical tissues that cannot resolve heteroplasmy, particularly cardiac and skeletal muscle. Progressive metabolic stress in these tissues leads to severe pathology in adulthood, including pulmonary hypertension and heart failure, skeletal muscle wasting, frailty, and premature death. Symptom severity is strongly modulated by the nuclear context.

conclusionsMedical interventions that may generate DNPH should address potential incompatibilities between donor and recipient mtDNA.

Indexed as

FrailtyHeart DiseasesHypertension, PulmonaryAdultAnimalsDNA, MitochondrialHeteroplasmyHumansMiceMitochondriaDNA, MitochondrialDNA, mitochondrialhaplotypesheart diseasesheteroplasmyhypertension, pulmonarymiceoxidative phosphorylation

Identifiers

PMID35236094
PMCPMC8969846
OpenAlexW4214927386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.